View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 4, 2022

FDA clears Pardes’ IND application for oral Covid-19 antiviral drug

With the IND clearance, the company intends to start Phase I clinical trials of PBI-0451 in the US.

The US Food and Drug Administration (FDA) has granted clearance to Pardes Biosciences’ Investigational New Drug (IND) application for its oral antiviral drug candidate, PBI-0451, to treat and prevent Covid-19. 

With the latest development, Pardes plans to commence Phase I clinical trials of PBI-0451 in the US. 

An orally bioavailable direct-acting antiviral (DAA) main protease (Mpro) inhibitor, PBI-0451 is under development for preventing and treating Covid-19 infection caused by the SARS-CoV-2 virus as well as associated ailments.

Mpro is an essential protein needed for coronaviruses replication.

At present, PBI-0451 is being analysed in a Phase I dose-escalation clinical trial in New Zealand.

The blinded, placebo-controlled, randomised trial is designed to assess PBI-0451’s safety, tolerability and pharmacokinetics following single and multiple ascending dose administration.

The company expects trial results in the current quarter of this year.

Pardes Biosciences CEO Uri Lopatin said: “As we enter our third year of a global pandemic, we believe the value of oral direct-acting antivirals for SARS-CoV-2 has become increasingly clear, especially if they can be given as standalone therapies. 

“Pending additional engagement with FDA and other regulators, we anticipate initiating our global Phase II/III studies of PBI-0451 in SARS-CoV-2 infected patients in mid-2022.”

The oral drug was demonstrated to hinder replication of an extensive range of coronaviruses including SARS-CoV-2 across several in-vitro models in preclinical studies. 

In clinically enabling toxicity studies, it was also found to be well tolerated.

Pardes concluded business combination with special purpose acquisition company FS Development Corp. II in December last year to become a publicly-traded firm.

Related Companies

Free Whitepaper

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy